Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals

Fandos, Noelia; Pérez‐Grijalba, Virginia; Pesini, Pedro; Olmos, Salvador; Bossa, Matías; Villemagne, Victor L.; Doecke, James; Fowler, Christopher; Masters, Colin L.; Sarasa, Manuel; AIBL Research Group

doi:10.1016/j.dadm.2017.07.004

Cited by 187Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals

Open access

Fandos, Noelia, Pérez‐Grijalba, Virginia, Pesini, Pedro, Olmos, Salvador, Bossa, Matías, Villemagne, Victor L., Doecke, James, Fowler, Christopher +3 more·2017·Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

DOI 10.1016/j.dadm.2017.07.004PMC PMC5602863

Open this paper in CoChat — free account Open PDF

Abstract

Introduction: Plasma amyloid β (Aβ) peptides have been previously studied as candidate biomarkers to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Methods: Free and total Aβ42/40 plasma ratios (FP42/40 and TP42/40, respectively) were determined using ABtest assays in cognitively normal subjects from the Australian Imaging, Biomarker and Lifestyle Flagship Study. This population was followed‐up for 72 months and their cortical Aβ burden was assessed with positron emission tomography. Results: Cross‐sectional and longitudinal analyses showed an inverse association of Aβ42/40 plasma ratios and cortical Aβ burden. Optimized as a screening tool, TP42/40 reached 81% positive predictive value of high cortical Aβ burden, which represents 110% increase over the population prevalence of cortical Aβ positivity. Discussion: These findings support the use of plasma Aβ42/40 ratios as surrogate biomarkers of cortical Aβ deposition and enrichment tools, reducing the number of subjects submitted to invasive tests and, consequently, recruitment costs in clinical trials targeting cognitively normal individuals.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.dadm.2017.07.004

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Few blood markers exist for the presymptomatic stage of Alzheimer's disease, though some progress has been reported for blood amyloid-β, tau, and NfL.
“Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking, although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in the blood have been reported5–10.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [5]
The present Elecsys assays produced among the best accuracies and are the first fully automated assays to have these greater accuracies.
“Although previous studies have found associations between CSF and PET Aβ and plasma Aβ using different immunoassays,7,12,13,14,44,45 the present Elecsys assays produced among the best accuracies and they are the first fully automated assays to have these greater accuracies.”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [12]
Many candidate blood biomarkers have failed in replication studies, but somewhat promising results have been seen for plasma tau, NFL, and combinations of Aβ42 and Aβ40.
“Many candidate blood biomarkers have failed in replication studies,7,8 but somewhat promising results have been seen for plasma tau, neurofilament light chain (NFL), and combinations of Aβ42 and Aβ40.9,10,11,12,13,14,15,16,17”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [12]
More recent studies have demonstrated that the plasma Aβ42/Aβ40 ratio correlates with brain Aβ and can differentiate patients with AD from healthy control participants.
“more recent studies have demonstrated that it correlates with brain Aβ and can differentiate patients with AD from healthy control participants.12,13”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [12]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069 · see citing works
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279 · see citing works
Self-citation
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,641 · see citing works
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426 · see citing works
Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1× · see citing works
“8 [27], which could seriously skew the results of any test and is almost certainly a relevant source of variability between studies.”
Background
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002 · see citing works
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · see citing works
Self-citation
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease
Ellis, K. A., Bush, A. I., Darby, D., Fazio, D. D., Foster, J. K., Hudson, P. J., Lautenschlager, N. T., Lenzo, N. P., Martins, R. N., Maruff, P. T., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 970 · see citing works
Self-citation
-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · see citing works
Self-citation
DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study
Lombardo, I., Ramaswamy, G., Piscitelli, S. C., & Friedhoff, L. T. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.154 · Cited by 656 · see citing works
18 F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R. R., Laere, K. V., Ivanoiu, A., Salmon, É., Bastin, C., Triau, E., Hasselbalch, S. G., Law, I. G., Andersen, A., Kørner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 649 · see citing works
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626 · see citing works
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550 · see citing works
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works
Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70501-4 · Cited by 458 · see citing works
<scp>CSF</scp> Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456 · see citing works
Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease
Graff‐Radford, N. R., Crook, J. E., Lucas, J. A., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.354 · Cited by 441 · see citing works
Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma
Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331 · see citing works
The future of blood‐based biomarkers for Alzheimer's disease
Henriksen, K., O’Bryant, S. E., Hampel, H. J., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H. D., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.013 · Cited by 312 · see citing works
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Initiative, T. A. D. N., Shaw, L. M. J., Vanderstichele, H., Knapik-Czajka, M. E., Figurski, M., Coart, E., Blennow, K., Soares, H. D., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 297 · see citing works
Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
Hansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andréasson, U., Londos, E., Wallin, A., Minthon, L., & Blennow, K. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.027 · Cited by 276 · see citing works
Association of Plasma β-Amyloid Level and Cognitive Reserve With Subsequent Cognitive Decline
Yaffe, K. S. (2011) · JAMA · doi:10.1001/jama.2010.1995 · Cited by 244 · see citing works
Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing
Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222 · see citing works
Self-citation
Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline
Koyama, A. K., Okereke, O. I., Yang, T., Blacker, D., Selkoe, D. J., & Grodstein, F. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1841 · Cited by 220 · see citing works
High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's Disease
Kuo, Y., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., Cotter, R. J., & Roher, A. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0552 · Cited by 182 · see citing works
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI
Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S. S., Petersen, R. C., Weiner, M. W., Jack, C. R., Jagust, W., DeCarli, C. S., Toga, A. W., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0861-8 · Cited by 177 · see citing works
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study
López, O. L., Kuller, L. H., Mehta, P. D., Becker, J. T., Gach, H. M., Sweet, R. A., Chang, Y., Tracy, R. P., & DeKosky, S. T. (2008) · Neurology · doi:10.1212/01.wnl.0000306696.82017.66 · Cited by 158 · see citing works
Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
Lui, J., Laws, S., Li, Q.-X., Villemagne, V., Ames, D., Brown, B., Bush, A., Ruyck, K. D., Dromey, J., Ellis, K., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-090249 · Cited by 141 · see citing works
Self-citation
Association of plasma amyloid β with risk of dementia
Lambert, J., Schraen-Maschke, S., Richard, F., Fiévet, N., Rouaud, O., Berr, C., Dartigues, J., Tzourio, C., Alpérovitch, A., Buée, L., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b78448 · Cited by 140 · see citing works
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Toledo, J. B., Shaw, L. M. J., & Trojanowski, J. Q. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt162 · Cited by 135 · see citing works
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li, Q., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.006 · Cited by 132 · see citing works
Self-citation
Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study
Chouraki, V. A., Beiser, A., Younkin, L. H., Preis, S. R., Weinstein, G., Hansson, O., Skoog, I. G., Lambert, J., Au, R., Launer, L. J., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.07.001 · Cited by 120 · see citing works
Impaired Lipoprotein Receptor-Mediated Peripheral Binding of Plasma Amyloid-β is an Early Biomarker for Mild Cognitive Impairment Preceding Alzheimer's Disease
Sagare, A. P., Deane, R., Zetterberg, H., Wallin, A., Blennow, K., & Zloković, B. V. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101248 · Cited by 80 · see citing works
Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease
Lövheim, H., Elgh, F., Johansson, A. S., Zetterberg, H., Blennow, K., Hallmans, G., & Eriksson, S. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.004 · Cited by 80 · see citing works
The use of SELDI-TOF MS in the search for biological markers of Alzheimer’s disease
Watt, A. D. (2013) · Minerva Access (University of Melbourne) · Cited by 75 · see citing works
How to handle adsorption of cerebrospinal fluid amyloid β (1–42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio
Willemse, E. A. J., van Uffelen, K. W. J., Brix, B., Engelborghs, S., Vanderstichele, H., & Teunissen, C. E. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.010 · Cited by 75 · see citing works
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
Insel, P. S., Ossenkoppele, R., Gessert, D., Jagust, W., Landau, S. M., Hansson, O., Weiner, M. W., & Mattsson, N. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00281 · Cited by 75 · see citing works
Therapeutic Albumin Binding to Remove Amyloid-β
Costa, M., Ortiz, A. M., & Jorquera, J. I. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111139 · Cited by 52 · see citing works
Assessing risk for preclinical β‐amyloid pathology with APOE , cognitive, and demographic information
Insel, P. S., Palmqvist, S., Mackin, R. S., Nosheny, R. L., Hansson, O., Weiner, M. W., Mattsson, N., & Initiative, A. D. N. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.07.002 · Cited by 52 · see citing works
Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment
Devanand, D. P., Schupf, N., Stern, Y., Parsey, R. V., Pelton, G. H., Mehta, P. D., & Mayeux, R. P. (2011) · Neurology · doi:10.1212/wnl.0b013e318224afb7 · Cited by 50 · see citing works
Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden
Rembach, A., the AIBL Research Group, Watt, A. D., Wilson, W. J., Villemagne, V. L., Burnham, S. C., Ellis, K. A., Maruff, P., Ames, D., Rowe, C. C., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131802 · Cited by 48 · see citing works
Self-citation
Variability in Blood-Based Amyloid-β Assays: The Need for Consensus on Pre-Analytical Processing
Watt, A. D., Perez, K. A., Rembach, A., Masters, C. L., Villemagne, V. L., & Barnham, K. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120058 · Cited by 38 · see citing works
Self-citation
En Attendant Centiloid
Villemagne, V. L. (2014) · Advances in Research · doi:10.9734/air/2014/11599 · Cited by 37 · see citing works
Self-citation
Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma
Pérez‐Grijalba, V., Fandos, N., Canudas, J., Insua, D., Casabona, D., Lacosta, A. M., Montañés, M., Pesini, P., & Sarasa, M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160325 · Cited by 26 · see citing works
Self-citation
Serum Aβ Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort
Abdullah, L. I., Luis, C. A., Paris, D., Mouzon, B., Ait‐Ghezala, G., Keegan, A. P., Wang, D., Crawford, F., & MULLAN, M. J. (2009) · Molecular Medicine · doi:10.2119/molmed.2009.00083 · Cited by 22 · see citing works
Several Direct and Calculated Biomarkers from the Amyloid-β Pool in Blood are Associated with an Increased Likelihood of Suffering from Mild Cognitive Impairment
Pérez‐Grijalba, V., Pesini, P., Monleón, I., Boada, M., Tárraga, L., Ruiz, A., Martínez‐Lage, P., José, I. S., & Sarasa, M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121744 · Cited by 19 · see citing works
Self-citation
BEYOND THE CONTROVERSY ON Aß BLOOD-BASED BIOMARKERS
Pesini, P., & Sarasa, M. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.35 · Cited by 3 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912 · see citing works
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · see citing works
Self-citation
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435 · see citing works
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study
de Wolf, F., Ghanbari, M., Licher, S., McRae‐McKee, K., Gras, L. A., Weverling, G. J., Wermeling, P. R., Sedaghat, S., Ikram, M. K., Waziry, R., et al. (2020) · Brain · doi:10.1093/brain/awaa054 · Cited by 328 · see citing works
Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species
Chen, X., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 291 · see citing works
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
Verberk, I. M. W., Misdorp, E. O., Koelewijn, J., Ball, A. J., Blennow, K., Dage, J. L., Fandos, N., Hansson, O., Hirtz, C., Janelidze, S., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12510 · Cited by 241 · see citing works
Self-citation
Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases
Wu, Y.-Y., & Kuo, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00636-z · Cited by 213 · see citing works
Total Aβ 42 /Aβ 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
Doecke, J. D., Pérez‐Grijalba, V., Fandos, N., Fowler, C. J., Villemagne, V. L., Masters, C. L., Pesini, P., & Sarasa, M. (2020) · Neurology · doi:10.1212/wnl.0000000000009240 · Cited by 190 · see citing works
Self-citation
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
Vergallo, A., Mégret, L., Lista, S., Cavedo, E., Zetterberg, H., Blennow, K., Vanmechelen, E., Vos, A. D., Habert, M., Potier, M., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.03.009 · Cited by 173 · see citing works
Self-citation
Detection and treatment of Alzheimer’s disease in its preclinical stage
Rafii, M. S., & Aisen, P. S. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 173 · see citing works
Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease
Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., Burnham, S. C., Bush, A. I., Chadunow, C., Collins, S., et al. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210005 · Cited by 164 · see citing works
Self-citation
Clinical Research on Alzheimer’s Disease: Progress and Perspectives
Sun, B., Li, W., Zhu, C., Jin, W., Zeng, F., Liu, Y.-H., Bu, X., Zhu, J., Yao, X., & Wang, Y. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0249-z · Cited by 164 · see citing works
Circadian modulation by time-restricted feeding rescues brain pathology and improves memory in mouse models of Alzheimer’s disease
Whittaker, D. S., Akhmetova, L., Carlin, D., Romero, H., Welsh, D. K., Colwell, C. S., & Desplats, P. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.014 · Cited by 147 · see citing works
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 142 · see citing works
Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study
Pérez‐Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., José, I. S., Arbizu, J., Martínez‐Lage, P., Munuera, J., Ruiz, A., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.41 · Cited by 133 · see citing works
Self-citation
PET staging of amyloidosis using striatum
Hanseeuw, B. J., Betensky, R. A., Mormino, E. C., Schultz, A. P., Sepulcre, J., Becker, J. A., Jacobs, H. I. L., Buckley, R. F., LaPoint, M. R., Vannini, P., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.04.011 · Cited by 134 · see citing works
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis
Meyer, S. D., Schaeverbeke, J. M., Verberk, I. M. W., Gille, B., Schaepdryver, M. D., Luckett, E. S., Gabel, S., Bruffaerts, R., Mauroo, K., Thijssen, E. H., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00728-w · Cited by 100 · see citing works
Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
Risacher, S. L., Fandos, N., Romero, J., Sherriff, I., Pesini, P., Saykin, A. J., & Apostolova, L. G. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.05.007 · Cited by 96 · see citing works
Self-citation
Plasma β-Amyloid in Mild Behavioural Impairment – Neuropsychiatric Symptoms on the Alzheimer’s Continuum
Miao, R., Chen, H.-Y., Gill, S., Naude, J., Smith, E., & Ismail, Z. (2021) · medRxiv · doi:10.1177/08919887211016068 · Cited by 93 · see citing works
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
Leuzy, A., Cullen, N. C., Mattsson, N., & Hansson, O. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000904 · Cited by 87 · see citing works
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 90 · see citing works
Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
Thijssen, E. H., Verberk, I. M. W., Vanbrabant, J., Koelewijn, A., Heijst, H., Scheltens, P., van der Flier, W. M., Vanderstichele, H., Stoops, E., & Teunissen, C. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-89004-x · Cited by 85 · see citing works
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
Startin, C. M., Ashton, N. J., Hamburg, S., Hithersay, R., Wiseman, F. K., Mok, K. Y., Hardy, J., Lleó, A., Lovestone, S., Parnetti, L., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0477-0 · Cited by 85 · see citing works
Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
Tosun, D., Veitch, D. P., Aisen, P. S. S., Jack, C. R., Jagust, W. J., Petersen, R. C., Saykin, A. J., Bollinger, J., Ovod, V., Mawuenyega, K. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab008 · Cited by 85 · see citing works
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Mattsson, N., Palmqvist, S., Blennow, K., & Hansson, O. (2020) · Nature Communications · doi:10.1038/s41467-020-19957-6 · Cited by 69 · see citing works
Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting
Zeng, X., Chen, Y., Sehrawat, A., Lee, J., Lafferty, T. K., Kofler, J., Berman, S. B., Sweet, R. A., Tudorascu, D., Klunk, W. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00711-1 · Cited by 73 · see citing works
Self-citation
The Protective Effect of Exercise in Neurodegenerative Diseases: The Potential Role of Extracellular Vesicles
Fuller, O. K., Whitham, M., Mathivanan, S., & Febbraio, M. A. (2020) · Cells · doi:10.3390/cells9102182 · Cited by 60 · see citing works
The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer’s Disease
Fan, L., Tzen, K., Chen, Y., Chen, T., Lai, Y., Yen, R., Huang, Y.-Y., Shiue, C., Yang, S., & Chiu, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00175 · Cited by 62 · see citing works
Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report
Bateman, R. J., Blennow, K., Doody, R. S., Hendrix, S. B., Lovestone, S., Salloway, S., Schindler, R. J., Weiner, M. W., Zetterberg, H., Aisen, P. S. S., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.21 · Cited by 61 · see citing works
A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
Shahpasand‐Kroner, H., Klafki, H.-W., Bauer, C., Schuchhardt, J., Hüttenrauch, M., Stazi, M., Bouter, C., Wirths, O., Vogelgsang, J. S., & Wiltfang, J. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0448-x · Cited by 61 · see citing works
Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease
Youn, Y. C., Kang, S., Suh, J., Park, Y. H., Kang, M. J., Pyun, J., Choi, S. H., Jeong, J. H., Park, K. W., Lee, H., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0499-7 · Cited by 61 · see citing works
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
The AB255 Study Group, Pérez‐Grijalba, V., Arbizu, J., Romero, J., Prieto, E., Pesini, P., Sarasa, L., Guillén, F., Monleón, I., José, I. S., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0549-1 · Cited by 56 · see citing works
Self-citation
Biomarkers of Alzheimer Disease
Budelier, M. M., & Bateman, R. J. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.030080 · Cited by 57 · see citing works
Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)
study, O. B. O. T. F., de Rojas, I., Romero, J., Rodríguez‐Gómez, O., Pesini, P., Sanabria, Á., Pérez‐Cordón, A., Ruiz, C. A., Hernández, I., Rosende‐Roca, M., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0444-1 · Cited by 53 · see citing works
Self-citation
Towards point-of-care diagnosis of Alzheimer’s disease: Multi-analyte based portable chemiresistive platform for simultaneous detection of β-amyloid (1–40) and (1–42) in plasma
Supraja, P., Tripathy, S., Singh, R., Singh, V., Chaudhury, G., & Singh, S. G. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113294 · Cited by 53 · see citing works
Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment
NAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 52 · see citing works
Diagnosis and Treatment of Alzheimer’s Disease:
Bomasang-Layno, E., & Bronsther, R. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.09.009 · Cited by 52 · see citing works
Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Duff, E. P., Zetterberg, H., Heslegrave, A., Dehghan, A., Elliott, P., Allen, N. E., Runz, H., Laban, R., Veleva, E., Whelan, C. D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03426-4 · Cited by 57 · see citing works
Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease
Chatterjee, P., Elmi, M., Goozee, K. G., Shah, T. M., Sohrabi, H. R., Dias, C. B., Pedrini, S., Shen, K., Asih, P. R., Dave, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190533 · Cited by 50 · see citing works
Aβ and tau structure‐based biomarkers for a blood‐ and CSF‐based two‐step recruitment strategy to identify patients with dementia due to Alzheimer's disease
Nabers, A., Hafermann, H., Wiltfang, J., & Gerwert, K. B. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.008 · Cited by 49 · see citing works
Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease
Lim, Y. Y., Maruff, P. T., Kaneko, N., Doecke, J. D., Fowler, C. J., Villemagne, V. L., Kato, T., Rowe, C. C., Arahata, Y., Iwamoto, S., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200475 · Cited by 48 · see citing works
Self-citation
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 48 · see citing works
Self-citation
Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
Hampel, H. J., Goetzl, E. J., Kapogiannis, D., Lista, S., & Vergallo, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00310 · Cited by 47 · see citing works
Anti-depressive-like and cognitive impairment alleviation effects of Gastrodia elata Blume water extract is related to gut microbiome remodeling in ApoE−/− mice exposed to unpredictable chronic mild stress
Huang, H., Lin, Y., Panyod, S., Chen, R.-A., Lin, Y., Chai, L. M. X., Hsu, C., Wu, W., Lu, K., Huang, Y., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115872 · Cited by 47 · see citing works
Understanding machine learning applications in dementia research and clinical practice: a review for biomedical scientists and clinicians
Wang, Y., Liu, S., Spiteri, A. G., Huynh, A. L. H., Chu, C., Masters, C. L., Goudey, B., Pan, Y., & Jin, L. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01540-6 · Cited by 48 · see citing works
Self-citation
Exploring Relationships Among Peripheral Amyloid Beta, Tau, Cytokines, Cognitive Function, and Psychosomatic Symptoms in Breast Cancer Survivors
Henneghan, A. M., Haley, A. P., & Kesler, S. R. (2019) · Biological Research For Nursing · doi:10.1177/1099800419887230 · Cited by 45 · see citing works
A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease
Xu, C., Zhao, L., & Dong, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220673 · Cited by 44 · see citing works
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 47 · see citing works
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 43 · see citing works
Amyloid-β as a Blood Biomarker for Alzheimer’s Disease: A Review of Recent Literature
Wang, X., Sun, Y., Li, T., Cai, Y., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190714 · Cited by 42 · see citing works
Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
Hayato, S., Takenaka, O., Reddy, S. H. S., Landry, I. S., Reyderman, L., Koyama, A., Swanson, C. J., Yasuda, S., & Hussein, Z. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12862 · Cited by 41 · see citing works
Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
Pascual‐Lucas, M., Allué, J. A., Sarasa, L., Fandos, N., Castillo, S., Terencio, J. V., Sarasa, M., Tartari, J. P., Sanabria, Á., Tárraga, L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01143-z · Cited by 41 · see citing works
Self-citation
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort
Jang, H., Kim, J. S., Lee, H. J., Kim, C., Na, D. L., Kim, H. J., Allué, J. A., Sarasa, L., Castillo, S., Pesini, P., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00911-7 · Cited by 36 · see citing works
Self-citation
Biomarkers in neurodegenerative diseases: a broad overview
Sathish, S., & Ayyavoo, V. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00075 · Cited by 38 · see citing works
Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer’s Disease
Chen, T., Lai, Y.-H., Ke, T.-L., Chen, J.-P., Lee, Y.-J., Lin, S.-Y., Lin, P.-C., Wang, P., & Cheng, I. H.-J. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000505435 · Cited by 36 · see citing works
Plasma Amyloid Concentration in Alzheimer’s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer’s Disease Cases from Controls
Feinkohl, I., Schipke, C. G., Kruppa, J., Menne, F., Winterer, G., Pischon, T., & Peters, O. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200046 · Cited by 36 · see citing works
A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease
Gessi, S., Poloni, T. E., Negro, G., Varani, K., Pasquini, S., Vincenzi, F., Borea, P. A., & Merighi, S. (2021) · Cells · doi:10.3390/cells10092344 · Cited by 35 · see citing works
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population
Zhu, F., Wolters, F. J., Yaqub, A., Leening, M. J. G., Ghanbari, M., Boersma, E. H., Ikram, M. A., & Kavousi, M. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.09.006 · Cited by 33 · see citing works
A SERS nanocellulose-paper-based analytical device for ultrasensitive detection of Alzheimer's disease
Yuan, W., Yuan, H., Li, R., Yong, R., Mitrović, I. Z., Lim, E. G., Duan, S., & Song, P. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.342447 · Cited by 33 · see citing works
Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease
Vogelgsang, J. S., Shahpasand‐Kroner, H., Vogelgsang, R., Streit, F., Vukovich, R., & Wiltfang, J. (2018) · Experimental Brain Research · doi:10.1007/s00221-018-5210-x · Cited by 32 · see citing works
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain
Burnham, S. C., Fandos, N., Fowler, C. J., Pérez‐Grijalba, V., Doré, V., Doecke, J. D., Shishegar, R., Cox, T. O., Fripp, J., Rowe, C. C., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa041 · Cited by 32 · see citing works
Self-citation
Plasma Aβ 42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study
Albani, D., Marizzoni, M., Ferrari, C., Fusco, F., Boeri, L., Raimondi, I., Jovicich, J., Babiloni, C., Soricelli, A., Lizio, R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180321 · Cited by 31 · see citing works
Spatial organization of protein aggregates on red blood cells as physical biomarkers of Alzheimer’s disease pathology
Nirmalraj, P. N., Schneider, T. R., & Felbecker, A. (2021) · Science Advances · doi:10.1126/sciadv.abj2137 · Cited by 28 · see citing works
A dual-screening electrochemiluminescent aptasensor based on a mesoporous silica nano-sieve for specific detection of amyloid-β monomer
Tan, R., Wang, Y., Mi, X., Li, H., & Tu, Y. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.131065 · Cited by 31 · see citing works
Plasma Biomarkers of Alzheimer's Disease and Neurodegeneration According to Sociodemographic Characteristics and Chronic Health Conditions
Zheng, H., Wu, Z., Mielke, M. M., Murray, A. M., & Ryan, J. L. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.142 · Cited by 30 · see citing works
Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome
Edwards, N. C., Lao, P. J., Alshikho, M. J., Ericsson, O. M., Rizvi, B. M., Petersen, M. E., O’Bryant, S. E., Aguilar, L. F., Simoes, S., Mapstone, M. E., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae331 · Cited by 33 · see citing works
The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer’s Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression
Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 33 · see citing works
Aging and APOE ‐ε4 are determinative factors of plasma A β 42 levels
Nakamura, T., Kawarabayashi, T., Seino, Y., Hirohata, M., Nakahata, N., Narita, S., Itoh, K., Nakaji, S., & Shoji, M. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.635 · Cited by 29 · see citing works
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys
Noveir, S. D., Kerman, B. E., Xian, H., Meuret, C. J., Smadi, S., Martinez, A. E., Johansson, J., Zetterberg, H., Parks, B. A., Kuklenyik, Z., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01028-1 · Cited by 28 · see citing works
Relation of plasma β‐amyloid, clusterin, and tau with cerebral microbleeds: Framingham Heart Study
Romero, J. R., Demissie, S., Beiser, A., Himali, J. J., DeCarli, C. S., Levy, D. A., & Seshadri, S. S. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51066 · Cited by 29 · see citing works
Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health‐related comorbidities in a community‐dwelling cohort
Rudolph, M. D., Sutphen, C. L., Register, T. C., Whitlow, C. T., Sai, K. K. S., Hughes, T. M., Bateman, J. R., Dage, J. L., Russ, K. A., Mielke, M. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13835 · Cited by 25 · see citing works
Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population‐based study
Zhang, Y., Ferreira, P. C. L., Jacobsen, E. P., Bellaver, B., Pascoal, T. A., Snitz, B. E., Chang, C. H., Villemagne, V. L., Ganguli, M., & Karikari, T. K. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13829 · Cited by 25 · see citing works
Self-citation
Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer’s disease
Ravichandran, S., Snyder, P. J., Alber, J., Murchison, C., Chaby, L. E., Jeromin, A., & Arthur, E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01668-5 · Cited by 26 · see citing works
Amyloid-beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome
Stylianaki, I., Polizopoulou, Z. S., Theodoridis, A. M., Koutouzidou, G., Baka, R. D., & Papaioannou, N. G. (2020) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15812 · Cited by 26 · see citing works
Cross-Sectional and Longitudinal Associations Between Plasma Neurodegenerative Biomarkers and Physical Performance Among Community-Dwelling Older Adults
He, L., Barreto, P. D. S., Giudici, K. V., Aggarwal, G., Nguyen, A. D., Morley, J. E., Li, Y., Bateman, R. J., Vellas, B. J., for the MAPT/DSA Group, et al. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa284 · Cited by 26 · see citing works
The Association of Kidney Function with Plasma Amyloid-β Levels and Brain Amyloid Deposition
Sedaghat, S., Ji, Y., Hughes, T. M., Coresh, J., Grams, M. E., Folsom, A. R., Sullivan, K., Murray, A. M., Gottesman, R. F., Mosley, T. H., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220765 · Cited by 27 · see citing works
Neurotoxic Microglial Activation via IFNγ‐Induced Nrf2 Reduction Exacerbating Alzheimer's Disease
Kang, Y. J., Hyeon, S. J., McQuade, A., Lim, J., Baek, S. H., Diep, Y. N., Do, K., Jeon, Y., Jo, D., Lee, C. J., et al. (2024) · Advanced Science · doi:10.1002/advs.202304357 · Cited by 25 · see citing works
Pathway Analysis for Plasma β-Amyloid, Tau and Neurofilament Light (ATN) in World Trade Center Responders at Midlife
Kritikos, M., Clouston, S., Diminich, E. D., Deri, Y., Yang, X., Carr, M. A., Gandy, S., Sano, M. C., Bromet, E. J., & Luft, B. J. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00189-1 · Cited by 25 · see citing works
UsingDrosophilaModels of Amyloid Toxicity to Study Autophagy in the Pathogenesis of Alzheimer’s Disease
O’Keefe, L. V., & Denton, D. (2018) · BioMed Research International · doi:10.1155/2018/5195416 · Cited by 24 · see citing works
The Role of Age on Beta-Amyloid1–42 Plasma Levels in Healthy Subjects
Zecca, C., Pasculli, G., Tortelli, R., Dell’Abate, M. T., Capozzo, R., Barulli, M. R., Barone, R., Accogli, M., Arima, S., Pollice, A., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.698571 · Cited by 24 · see citing works
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease
Andersson, E., Schultz, N., Saito, T., Saido, T. C., Blennow, K., Gouras, G. K., Zetterberg, H., & Hansson, O. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01196-8 · Cited by 24 · see citing works
DTI-ALPS index as a predictor of cognitive decline over 1 year
Jungwon, J., Lee, J. H., Choi, C., & Lee, J. (2024) · Neuroradiology · doi:10.1007/s00234-024-03521-w · Cited by 23 · see citing works
Single-molecule studies of amyloid proteins: from biophysical properties to diagnostic perspectives
Wu, J., Cao, C., Loch, R. A., Tiiman, A., & Luo, J. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000086 · Cited by 23 · see citing works
Diffusion MRI relates to plasma Aβ42/40 in PET negative participants without dementia
DeSimone, J. C., Wang, W., Loewenstein, D., Duara, R., Smith, G. E., McFarland, K. N., Armstrong, M. J., Weber, D. M., Barker, W., Coombes, S. A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13693 · Cited by 22 · see citing works
A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma
Mehta, P. D., Patrick, B. A., Miller, D. L., Coyle, P. K., & Wısnıewskı, T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200861 · Cited by 22 · see citing works
The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status
Ashford, M. T., Veitch, D. P., Neuhaus, J. M., Nosheny, R. L., Tosun, D., & Weiner, M. W. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12253 · Cited by 22 · see citing works
Association of Plasma Aβ 42 /Aβ 40 Ratio and Late-Onset Epilepsy
Johnson, E. L., Sullivan, K., Schneider, A. L. C., Simino, J. M., Mosley, T. H., Kucharska‐Newton, A., Knopman, D. S., & Gottesman, R. F. (2023) · Neurology · doi:10.1212/wnl.0000000000207635 · Cited by 20 · see citing works
Plasma Phosphorylated-tau181 Is a Predictor of Post-stroke Cognitive Impairment: A Longitudinal Study
Huang, L., Chao, S., Hu, C., Chien, L., Chiou, H.-Y., Lo, Y., & Hsieh, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.889101 · Cited by 20 · see citing works
Peripheral metabolism of lipoprotein-amyloid beta as a risk factor for Alzheimer’s disease: potential interactive effects of APOE genotype with dietary fats
D’Alonzo, Z. J., Lam, V., Takechi, R., Nesbit, M., Vaccarezza, M., & Mamo, J. C. L. (2023) · Genes & Nutrition · doi:10.1186/s12263-023-00722-5 · Cited by 19 · see citing works
Potential association of bone mineral density loss with cognitive impairment and central and peripheral amyloid-β changes: a cross-sectional study
Zhang, P., Zhou, Y., Chen, G., Li, J., Wang, B., & Lu, X. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05580-7 · Cited by 15 · see citing works
Nanoparticle-based colorimetric sensors to detect neurodegenerative disease biomarkers
Fan, Q., Gao, Y., Mazur, F., & Chandrawati, R. (2021) · Biomaterials Science · doi:10.1039/d1bm01226f · Cited by 17 · see citing works
Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage
Li, T., Yang, Q. Z., Hu, X., & Han, Y. (2022) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 17 · see citing works
Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
Toniolo, S., Zhao, S., Scholcz, A., Amein, B., Ganse‐Dumrath, A., Heslegrave, A., Thompson, S., Manohar, S., Zetterberg, H., & Masud Husain, B. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12590 · Cited by 17 · see citing works
Clinical application of serological Alzheimer's disease diagnosis using a highly sensitive biosensor with hydrogel-enhanced dielectrophoretic force
Kim, H. J., Choi, W., Lee, J. S., Choi, J., Choi, N., & Hwang, K. S. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113668 · Cited by 17 · see citing works
Predicting Longitudinal Cognitive Decline and Alzheimer’s Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers
Park, M., Ahn, J., Kim, Y.-J., Lee, J., Lee, J.-C., Hwang, S., & Kim, K. (2024) · Cells · doi:10.3390/cells13131085 · Cited by 16 · see citing works
Plasma biomarkers of the amyloid pathway are associated with geographic atrophy secondary to age-related macular degeneration
Lashkari, K., Teague, G. C., Beattie, U. K., Betts, J. C., Kumar, S., McLaughlin, M., & López, F. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236283 · Cited by 16 · see citing works
Distinct Uptake Kinetics of Alzheimer Disease Amyloid-β 40 and 42 at the Blood-Brain Barrier Endothelium
Sharda, N., Ahlschwede, K. M., Curran, G. L., Lowe, V. J., & Kandimalla, K. K. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000086 · Cited by 13 · see citing works
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease
Winston, C. N., Langford, O., Levin, N., Raman, R., Yarasheski, K. E., West, T., Abdel‐Latif, S., Donohue, M., Nakamura, A., Toba, K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221118 · Cited by 16 · see citing works
Self-citation
Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer’s Disease
Brod, S. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215125 · Cited by 16 · see citing works

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
Vergallo, A., Mégret, L., Lista, S., Cavedo, E., Zetterberg, H., Blennow, K., Vanmechelen, E., Vos, A. D., Habert, M., Potier, M., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.03.009 · Cited by 173 · see citing works
Self-citation
Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study
Pérez‐Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., José, I. S., Arbizu, J., Martínez‐Lage, P., Munuera, J., Ruiz, A., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.41 · Cited by 133 · see citing works
Self-citation
Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
The AB255 Study Group, Pérez‐Grijalba, V., Arbizu, J., Romero, J., Prieto, E., Pesini, P., Sarasa, L., Guillén, F., Monleón, I., José, I. S., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0549-1 · Cited by 56 · see citing works
Self-citation
Total Aβ 42 /Aβ 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
Doecke, J. D., Pérez‐Grijalba, V., Fandos, N., Fowler, C. J., Villemagne, V. L., Masters, C. L., Pesini, P., & Sarasa, M. (2020) · Neurology · doi:10.1212/wnl.0000000000009240 · Cited by 190 · see citing works
Self-citation
Plasma amyloid‐beta42/40 ratio as biomarker of cerebral amyloidosis in cognitively unimpaired APOE‐e4 homozygotes, heterozygotes and non‐carriers
Jansen, W. J., Ghisays, V., DeMarco, K. L., Boker, C. A., Chen, K., Chen, Y., Luo, J., Protas, H. D., West, T., Meyer, M. R., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.040332

Authors: Fandos, N., Pérez‐Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., Doecke, J., Fowler, C., Masters, C. L., Sarasa, M., & AIBL Research Group
Affiliations: R&D Department Araclon Biotech Ltd. Zaragoza Spain
Universidad de Zaragoza (ES)
The University of Melbourne (AU)
Commonwealth Scientific and Industrial Research Organisation (AU)
Corresponding author: Pesini, Pedro
ORCID: Pérez‐Grijalba, Virginia
Pesini, Pedro
Olmos, Salvador
Bossa, Matías
Villemagne, Victor L.
Doecke, James
Fowler, Christopher
Masters, Colin L.
Venue: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher: Wiley
Published: 2017-01
Volume: 8
Issue: 1
Pages: 179-187
ISSN: 2352-8729 (ISSN-L)
DOI: 10.1016/j.dadm.2017.07.004
PMC: PMC5602863
OpenAlex: W2750795037
Cited by: 187
References: 52
Citations by year: 2026: 9 · 2025: 20 · 2024: 22 · 2023: 27 · 2022: 20 · 2021: 32 · 2020: 23 · 2019: 18 · 2018: 16
FWCI: 12.81
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 241 d)
Locations: Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords: amyloid-beta, Alzheimer's disease biomarkers, cognitively normal individuals, clinical trial recruitment, screening tool, positron emission tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks